X
skip to main content
Logo
  • June 30, 2017

    Two features articles published by VICE Sports for Canada 150 are calling Terry Fox the most important athlete in Canadian history whose cancer research legacy lives on.

  • June 30, 2017

    New research from a TFRI-funded team suggests screening for lung cancer could save money – and lives – especially if it also identifies other tobacco-related conditions in high-risk individuals.

  • June 22, 2017

    Terry’s dream was to fund research to cure cancer, and he inspired us with that dream. We believe that it is through research that cures to cancer will be found, and survival rates for even the most challenging cancers will continue to increase.

  • May 29, 2017

    Dr. Victor Ling, president and scientific director of The Terry Fox Research Institute, has been recognized by The Vancouver Sun for his breakthrough in fighting drug-resistant cancers.

  • May 24, 2017

    The drug metformin is typically used to treat Type 2 diabetes, and some cancer patients have shown improved outcome when given the drug. A recent study by TFRI’s hypoxia group sheds new light on biomarkers that may indicate the drug’s efficacy in patients.

  • May 24, 2017

    TFRI’s long-funded program project on human leukemia has made groundbreaking progress in the quest to expand human blood stem cells for therapeutic purposes.

  • May 24, 2017

    What if there was a way to predict if leukemia patients would respond to standard treatment or not? A TFRI-funded team has developed a novel, 17-gene signature test from leukemia stem cells (LSCs) that determines just that.

  • May 24, 2017

    Understanding why some prostate cancer tumours are indolent while others eventually kill patients is the focus of many within the global cancer research community. A top Canadian research team has provided new answers with the potential to change the way aggressive tumours are treated and, importantly, improve cure rates.

  • May 24, 2017

    The use of oncolytic viruses to stimulate a patient’s immune system as well as directly kill tumour cells is a novel approach to eradicating cancer, but antibodies that permanently inactivate the virus are often generated that counter treatment efficacy. An Ottawa-based lab has come up with a way of countering this problem by using a complement inhibitor that prevents the virus’ neutralization, thereby ensuring viral vectors reach their target.

  • May 18, 2017

    The finding by a B.C. team studying rare and forme fruste tumours is important in that it may help to identify women at risk of relapse for the disease, as well as to provide a non-invasive way to monitor patients in follow-up.

  • May 17, 2017

    An article published in The National Post in mid-May has identified the Terry Fox Foundation as one of the best places to donate to cancer research in Canada.

  • April 25, 2017

    Awards to four New Investigators were recently made, with each award valued at $450,000 for a term of three years. Recipients are: Dr. Housheng Hansen He (UHN), Dr. Frédérick Mallette (UdeM), and Dr. Peter Stirling (BC Cancer Agency), and Dr. Trevor Pugh.

  • March 24, 2017

    TFRI New Investigator Paul Boutros is among a team of researchers who have found a new test that can help to determine men at high risk for aggressive prostate cancer. The findings, published in The Journal of the National Cancer Institute, could help fill an unmet need for reliable genetic testing for prostate cancer from a simple blood sample.

  • February 15, 2017

    New Brunswick-led national research team aims for tailored treatments for patients with incurable multiple myeloma through Terry Fox Research Institute's $5-million investment.

  • February 15, 2017

    In the House of Commons today, Cambridge MP Bryan May congratulated TFRI and its joint pilot project partners -- The Princess Margaret Cancer Centre and the BC Cancer Agency -- for their new partnership to accelerate precision medicine. You can listen to his remarks on You Tube or read them below.

Back to Top